Multimodal Intervention for Persistent Musculoskeletal Pain in Primary Care

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorUniversitat Jaume I

About this trial

This multicenter randomized controlled trial aims to evaluate the effectiveness of a multimodal intervention for the active management of persistent musculoskeletal pain in primary care. The intervention combines pain neuroscience education, therapeutic exercise, and the promotion of self-care and healthy lifestyle habits to improve health-related quality of life in adults with persistent nonspecific musculoskeletal pain lasting at least six months.

A total of 146 participants aged 18 to 70 years will be recruited from five primary care centers in the Comunitat Valenciana (Spain) and randomly assigned to either the experimental group or the control group. The primary outcome is health-related quality of life measured using the SF-36 Health Survey. Secondary outcomes include pain intensity, pain catastrophizing, kinesiophobia, central sensitization, emotional symptoms, perceived social support, medication use, and lifestyle-related variables. Assessments will be conducted at baseline, post-intervention, 6 months, and 12 months follow-up.

Eligibility criteria

Qualifiers

Adults aged between 18 and 70 years

Diagnosis of nonspecific persistent musculoskeletal pain lasting at least 6 months

Receiving care in participating primary care centers

Ability to understand study procedures and provide written informed consent

Disqualifiers

Specific musculoskeletal pathology requiring specialized treatment (e.g., fracture, inflammatory rheumatic disease, malignancy)

Neurological disorders affecting movement or pain perception

Severe psychiatric disorders that may interfere with participation

Participation in another structured pain management program during the study period

Trial design

Treatments tested in this trial

  • Multimodal Pain Management Program
  • Usual Primary Care

Treatment groups

146 Participants
are divided into 2 treatment groups

Sponsors and collaborators